Search
Inavolisib
go.drugbank.com/drugs/DB15275ApprovedInvestigationalInavolisib is an inhibitor of PI3Kα that was approved by the FDA in October 2024 for the treatment of certain patients with advanced breast cancers. … _PIK3CA_ is one of the most frequently mutated oncogenes, with the resulting mutated p110α protein it encodes playing a central role in tumor cell proliferation.
Categories: Cytochrome P-450 CYP2B6 Inducers, Heterocyclic Compounds, 1-RingSynonyms: (2S)-2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-D)(1,4)benzoxazepin-9-yl)amino)propanamide, propanamide, 2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-D)(1,4)benzoxazepin-9-yl)amino)-, (2S)-Canfosfamide
go.drugbank.com/drugs/DB04972InvestigationalCanfosfamide is an active agent in chemotherapy-resistant ovarian cancer.
Busulfan
go.drugbank.com/drugs/DB01008ApprovedInvestigationalBusulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. … According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesSynonyms: 1, 4-Bis[methanesulfonoxy]butaneAmibegron
go.drugbank.com/drugs/DB05395InvestigationalAmibegron is an agonist for atypical beta3-adrenoceptors which inhibits intestinal motility.
Categories: Adrenergic beta-3 Receptor AgonistsInvert sugar
go.drugbank.com/drugs/DB09344ExperimentalIt is formed by an equal amount of glucose and fructose. It differentiates from sugar cane in the rotation of the polarized light, which in the case of invert sugar it is to the left (levorotatory). … [A32124] Invert sugar is FDA approved since 1988 as a safe substance (GRAS).
Categories: Compounds used in a research, industrial, or household settingPlicamycin
go.drugbank.com/drugs/DB06810ApprovedWithdrawnPlicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus.
Categories: Compounds used in a research, industrial, or household settingLetermovir
go.drugbank.com/drugs/DB12070ApprovedInvestigational[L1021] It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors.[A31290] Letermovir has recieved both priority and orphan drug status from the FDA.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: PREVYMİS 240 MG İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADET, PREVYMİS 480 MG İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADETDulaglutide
go.drugbank.com/drugs/DB09045ApprovedInvestigationalDulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct … therapy to diet and exercise in the management of 2 diabetes (T2DM).
Categories: Glucagon-like peptide-1 (GLP-1) analogues, GLP-1 AgonistsProducts: TRULICITY® 1.5 MG/0.5 ML, TRULICITY® 0.75 MG/0.5 MLOdevixibat
go.drugbank.com/drugs/DB16261ApprovedInvestigationalOdevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familial intrahepatic cholestasis (PFIC … [L34803] Previous therapies for PFIC included a bile acid sequestrant such as [ursodeoxycholic acid].
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 2-RingToripalimab
go.drugbank.com/drugs/DB15043ApprovedInvestigationalof T-cell proliferation and cytokine production, and thus its overexpression can inhibit T-cell-mediated immune surveillance of tumors. … The proliferation of some cancers can be attributed, at least in part, to the suppression of host tumor surveillance.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, Programmed Death Receptor-1 Blocking Antibody